There are two distinct issues here. I’m in favor of federal preemption for the same reason you are. However, I don’t think your argument (that drug companies can’t unilaterally update a product label) is a good vehicle to ensure the outcome you desire.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”